Pfizer Quality Improvement Request for Proposals: Improving the Vaccination Environment to Prevent Respiratory Infectious Diseases in Older Adults and High-Risk Individuals
Pfizer Inc. funds quality improvement projects to boost vaccination environments and uptake for respiratory diseases among older adults and high-risk individuals in Japan.
Funder: Pfizer Inc.
Due Dates: September 15, 2026 (Submission Deadline) | September 30, 2026 (Extended Deadline)
Funding Amounts: Up to 7,500,000 JPY per project; maximum project duration 2 years (with possible extension to 3 years)
Summary: Supports quality improvement projects to enhance vaccination environments and uptake for older adults and high-risk individuals in Japan.
Key Information: Only organizations (not individuals) in Japan are eligible; clinical research is not supported.
Description
This grant opportunity from Pfizer Inc. aims to fund quality improvement (QI) projects that enhance the environment for vaccination against respiratory infectious diseases—such as COVID-19, pneumococcal disease, and RSV—in older adults and high-risk individuals in Japan. The program seeks initiatives that address barriers to vaccination, improve access and communication, and implement system-based changes or educational interventions to increase vaccination uptake and patient confidence. Projects should be evidence-based, multidisciplinary, and tailored to the living environments of the target populations.
